Aspirin and diabetes

British Journal of Diabetes and Vascular Disease

Volumn 6, Issue 2, 2006, Pages 74-82

  Raghavan, Rajeev P ^a   Laight, David W ^b   Shaw, Kenneth M ^a   Cummings, Michael H ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Aspirin; Cycloxygenase; Diabetes; Endothelial function; Inflammation; Metabolic syndrome; NF B; Oxidative stress

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANGIOTENSIN II; ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CHOLESTEROL; CLOPIDOGREL; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 1; INTERLEUKIN 6; METFORMIN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXYNITRITE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; THIAZOLIDINE DERIVATIVE; THROMBOXANE A2;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; CYTOKINE RELEASE; DIABETIC ANGIOPATHY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESISTANCE; ENDOTHELIAL DYSFUNCTION; ENTERIC COATED TABLET; FIBRINOLYSIS; GASTROINTESTINAL TOXICITY; GLUCOSURIA; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IN VITRO STUDY; INSULIN RESISTANCE; LEUKOCYTE ADHERENCE; LOW DRUG DOSE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

EID: 33646576226     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514060060020501     Document Type: Review

References (73)

1. Laight DW, Carrier MJ, Anggard EE. Antioxidants, diabetes and endothelial dysfunction. Cardiovasc Res 2000;47:457-64.
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324: 71-86.
3. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. PPP Collaborative Group. Primary Prevention of Cardiovascular Events With Low-Dose Aspirin and Vitamin E in Type 2 Diabetic Patients Results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003;26:3264-72.
4. Stern MP. Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes 1995;44:369-74.
5. Day C. Diagnostic definitions - metabolic syndrome. Br J Diab Vasc Dis 2005;5:115-18.
6. Duffy SJ, Castle SF, Harper RW, Meredith IT Contribution of vasodilator prostanoids and nitric oxide to resting flow, metabolic vasodilation, and flow-mediated dilation in human coronary circulation. Circulation 1999;100:1951-7.
7. Tracy RP. Inflammation, the metabolic syndrome and cardiovascular risk. Int J Clin Prac. Suppl 2003;27:10-17.
8. Cominacini L, Rigoni A, Pasini AF et al. The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem 2001;276:13750-5.
9. Eisele G, Schwedhelm E, Schieffer B, Tsikas D, Boger RH. Acetylsalicylic acid inhibits monocyte adhesion to endothelial cells by an antioxidative mechanism. J Cardiovasc Pharm 2004;43:514-21.
10. Willerson JT, Ridker PM. Inflammation as cardiovascular risk factor Circulation 2004;109(suppl 1):II-2-10.
11. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-Reactive Protein Levels and Impaired Endothelial Vasoreactivity in Patients With Coronary Artery Disease. Circulation 2000;102:1000-06.
12. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004;63:582-92.
13. Johansen J, Harris A, Rychly D, Ergul A. Oxidative stress and the use of antioxidants in diabetes: Linking basic science to clinical practice. Cardiovasc Diabetol 2005;4:5.
14. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-7.
15. Ajjan R, Grant PJ, Futers TS et al. Complement C3 and C-reactive protein levels in patients with stable coronary artery disease. Thromb Haemost 2005;94:1048-53.
16. Hunt ME, O'Malley PG, Vernalis MN, Feuerstein IM, Taylor AJ. C-reactive protein is not associated with the presence or extent of calcified subclinical atherosclerosis. Am Heart J 2001;141:206-10.
17. Clapp BR, Hingorani AD, Kharbanda RK et al. Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress. Cardiovasc Res 2004;64:172-8.
18. Sagone AL Jr, Husney RM. Oxidation of salicylates by stimulated granulocytes: evidence that these drugs act as free radical scavengers in biological systems. J Immunol 1987;138:2177-83.
19. Aljada A, Mohanty P, Ghanim H et al. Increase in intranuclear nuclear factor kappaB and decrease in inhibitor kappaB in mononuclear cells after a mixed meal: evidence for a proinflammatory effect. Am J Clin Nutr 2004;79:682-90.
20. Helmersson J, Vessby B, Larsson A, Basu S. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation 2004;109:1729-34.
21. Chen CC, Rosenbloom CL, Anderson DC, Manning AM. Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expression by inhibitors of I kappa B-alpha phosphorylation. J Immunol 1995;155:3538-45.
22. Pierce JW, Read MA, Ding H, Luscinskas FW, Collins T. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol 1996; 156:3961-9.
23. Gawaz M, Page S, Massberg S et al. Transient platelet interaction induces MCP-1 production by endothelial cells via I kappa B kinase complex activation. Thromb Heamo 2002;88:307-14.
24. Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I kappa B/ NF-kappa B axis in obesity- and diet-induced insulin resistance. [Review]. International Journal of Obesity & Related Metabolic Disorders: J Intl Assoc Study of Obes 2003;27(suppl 3):S49-S52.
25. Yuan M, Konstantopoulos N, Lee J et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001;293:1673-7.
26. Dandona P, Aljada A, Mohanty P et al. Insulin Inhibits Intranuclear Nuclear Factor {{kappa}}B and Stimulates I{{kappa}}B in Mononuclear Cells in Obese Subjects: Evidence for an Anti-inflammatory Effect? J Clin Endocrinol Metab 2001;86:3257-65.
27. Hundal RS, Petersen-KF, Mayerson AB et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002;109:1321-6.
28. Blackwell TS, Christman JW. The Role of Nuclear Factor-kappa B in Cytokine Gene Regulation. Am J Respir Cell Mol Biol 1997;17:3-9.
29. American Diabetes Association Position statement. Aspirin therapy in diabetes. Diabetes Care 1997;20:1772-3.
30. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10(suppl1):S1-78.
31. JBS 2. Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(suppl 5):v1-52.
32. Cull CA, Neil HA, Holman RR. Changing aspirin use in patients with Type 2 diabetes in the UKPDS. Diabetic Medicine 2004;21:1368-71.
33. Klein L, Gheorghiade M. Management of the patient with diabetes mellitus and myocardial infarction: clinical trials update. Am J Med 2004;116(suppl5A):47s-63s.
34. Damci T, Kultursay H, Oguz A, Pehlivanoglu S, Tokgozoglu L; Vascular Risk Study Group. Sub-optimal drug treatment of diabetes and cardiovascular risk in diabetic patients in Turkey. A countrywide survey. Diabetes Metab 2004;30:327-33.
35. Watala C, Pluta J, Golanski J et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 2005;83:148-58.
36. Zanchetti A, Hansson L, Dahlof B et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens 2001;19:1149-59.
37. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992;268:1292-300.
38. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-5.
39. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006;116:4-15.
40. Costanzo A, Moretti F, Burgio VL et al. Endothelial activation by angiotensin II through NFkappaB and p38 pathways: Involvement of NFkappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J Cell Physiol 2003;195:402-10.
41. Serhan CN, Hong S, Gronert K et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Experiment Med 2002;196:1025-37.
42. Madajka M, Korda M, White J, Malinski T. Effect of aspirin on constitutive nitric oxide synthase and the bioavailability of NO. Throm Res 2003;110:317-21.
43. Dragomir E, Manduteanu I, Voinea M, Costache G, Manea A, Simionescu M. Aspirin rectifies calcium homeostasis, decreases reactive oxygen species, and increases NO production in high glucose-exposed human endothelial cells. J Diabetes Complications 2004;18:289-99.
44. Grosser N, Abate A, Oberle S et al. Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. Biochem Biophys Res Commun 2003;308:956-60.
45. Kharbanda RK, Walton B, Allen M et al. Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Circulation 2002;105:2600-04.
46. Husain S, Andrews NP. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998;97:716-20.
47. Takano T, Fiore S, Maddox JF, Brady HR, Petasis NA, Serhan CN. Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J Exp Med 1997;185:1693-704.
48. Fiorucci S, Distrutti E, Mencarelli A et al. Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin. Br J Pharmacol 2003;139:1351-9.
49. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999;100:793-8.
50. Feldman M, Jialal I, Devaraj S, Cryer B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 2001;37:2036-41.
51. Talbodec A, Berkane N, Blandin V et al. Aspirin and Sodium Salicylate Inhibit Endothelin ETA Receptors by an Allosteric Type of Mechanism. Mol Pharmacol 2000;57:797-804.
52. Ranganathan S, Joseph J, Mehta JL. Aspirin inhibits human coronary artery endothelial cell proliferation by upregulation of p53. Biochem Biophys Res Commun 2003;301:143-6.
53. Wu Rong, Lamontagne Daniel, de Champlain J. Antioxidative Properties of Acetylsalicylic Acid on Vascular Tissues From Normotensive and Spontaneously Hypertensive Rats. Circulation 2002;105:387-92.
54. Ristimae T, Zilmer M, Zilmer K et al. Effect of low-dose aspirin on the markers of oxidative stress. Cardiovasc Drugs Ther 1999;6:485-90.
55. Cipollone F, Ciabattoni G, Patrignani P et al. Oxidant Stress and Aspirin-Insensitive Thromboxane Biosynthesis in Severe Unstable Angina. Circulation 2000;102:1007-13.
56. Ashidate K, Kawamura M, Mimura D et al. Gentisic acid, an aspirin metabolite, inhibits oxidation of low-density lipoprotein and the formation of cholesterol ester hydroperoxides in human plasma. Eur J Pharmacol 2005;513:173-9.
57. Ersoz G, Tikiz H, Yakaryilmaz A, Tezcan K, Genc Y, Korkmaz S. Differential Effect of Aspirin on Platelet Aggregation in Patients with Coronary Artery Disease In Relation with Associated Risk Factors. Japanese Heart J 2003;44(1):21-9.
58. The Multicenter Salsalate/Aspirin Comparison Study Group. Does the acetyl group of aspirin contribute to the antiinflammatory efficacy of salicylic acid in the treatment of rheumatoid arthritis? The Multicenter Salsalate/Aspirin Comparison Study Group. J Rheumatology 1989;16: 321-7.
59. Kim JK, Kim Y, Fillmore JJ et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001;108:437-46.
60. Bjornsson TD, Schneider DE, Berger H Jr. Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther 1989;250:154-61.
61. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001;85:265-71.
62. Taylor DW, Barnett HJ, Haynes RB et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. Lancet 1999;353:2179-84.
63. Macchi L, Christiaens L, Brabant S et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Throm Res 2002;107:45-9.
64. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin. N Engl J Med 2001;345:1809-17.
65. Kurth T, Glynn RJ, Walker AM et al. Inhibition of Clinical Benefits of Aspirin on First Myocardial Infarction by Nonsteroidal Antiinflammatory Drugs. Circulation 2003;108:1191-5.
66. Dunn EJ, Ariens RA, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia 2005;48:1198-2006.
67. Meade TW, Brennan PJ. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ 2000;321:13-17.
68. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events. Circulation 2002;105:1650-5.
69. Bruno A, McConnell JP, Cohen SN et al. Serial Urinary 11-Dehydrothromboxane B2, Aspirin Dose, and Vascular Events in Blacks After Recent Cerebral Infarction. Stroke 2004;35:727-30.
70. Peters RJG, Mehta SR, Fox KAA et al. Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes: Observations From the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study. Circulation 2003;108:1682-87.
71. Ringleb PA, Bhatt DL, Hirsch AT, Topol EJ, Hacke W, for the CAPRIE Investigators. Benefit of Clopidogrel Over Aspirin Is Amplified in Patients With a History of Ischemic Events. Stroke 2004;35:528-32.
72. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998;396:15-17.
73. Matsunaga T, Hokari S, Koyama I, Harada T, Komoda T. NF-kappa B activation in endothelial cells treated with oxidized high-density lipoprotein. Biochem Biophys Res Commun 2003;303:313-19.